Who Paid My Doc
Randall Miller
Internal Medicine Eunice, LA Medical Doctor
NPI 1952341497 CMS profile 1244262
351 Moosa Blvd, Ste A, Eunice, LA 70535
General payments
$668
Research payments
$48,175
Ownership & investment interest
$0
Research they led as principal investigator
$1,190,760
Through program year 2024, Randall Miller of Eunice, LA is reported in the CMS Open Payments database as having received $668 across 23 general payments and $48,175 in research payments paid to them. Separately, studies naming them as principal investigator received $1,190,760 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $108 | 2 | |
| 2023 | General | $14 | 1 | |
| 2022 | General | $13 | 1 | |
| 2022 | Research | $48,175 | 1 | |
| 2021 | General | $262 | 8 | |
| 2020 | General | $174 | 7 | |
| 2019 | General | $97 | 4 |
Beside peers
- Randall Miller
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Randall Miller were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Randall Miller | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $97 | $159 | $48–$570 | $163 |
| 2020 | $174 | $119 | $33–$402 | $114 |
| 2021 | $262 | $135 | $37–$521 | $132 |
| 2022 | $13 | $141 | $42–$496 | $149 |
| 2023 | $14 | $149 | $45–$519 | $160 |
| 2024 | $108 | $154 | $47–$537 | $164 |
| 2025 | $0 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 173 drugsPart D claims
14,942
Drug cost
$927,469
Branded share of claims
22.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 138 | $148,192 | |
| Eliquis Apixaban | Brand | 182 | $112,601 | |
| Januvia Sitagliptin Phosphate | Brand | 153 | $99,737 | |
| Mounjaro Tirzepatide | Brand | 64 | $73,867 | |
| Farxiga Dapagliflozin Propanediol | Brand | 83 | $60,379 | |
| Entresto Sacubitril/Valsartan | Brand | 56 | $46,516 | |
| Jardiance Empagliflozin | Brand | 40 | $30,684 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 32 | $29,616 | |
| Xarelto Rivaroxaban | Brand | 28 | $25,485 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 41 | $25,076 |
The 10 drugs with the highest cost, of 173 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$185,588
Medicare patients
638
Services billed
10,693
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 56% | |
| Ischemic heart disease | 41% | |
| Diabetes | 38% | |
| Heart failure | 33% | |
| COPD | 28% | |
| Depression | 27% | |
| Atrial fibrillation | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 131 | 132 | $10,771 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 72 | 6,096 | $578 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 73 | 416 | $198 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 31 | 31 | $152 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 89 | 448 | $142 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 | Office | 15 | 68 | $9 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg J2001 | Office | 62 | 146 | $3 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
24 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Internal Medicine in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.